Only goes to my previous point that the CEO's business decisions are questionable at best. Someone previously posted about the relative merits of the HemaXellerate patent, I don't argue that either. My concern is that the business entity that owns the patent does not have the acumen to execute financing that will allow the patent mature into a fruitful treatment. Best thing that could happen for HemaXellerate is BMSN going belly-up and the patent being purchased by a company that can run with it.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.